Migraine Disorders
Conditions
Brief summary
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
Detailed description
This is a retrospective database study that aims to explore the reliability of effect with acute use of Rimegepant or triptans, to evaluate the satisfaction with Rimegepant or triptans, to evaluate willingness to continue using Rimegepant or triptans, and to explore proportion optimized on treatment with Rimegepant or triptans. The data will be extracted from the Adelphi Real World (ARW) Migraine Disease Specific ProgrammeTM (DSP) 2022 database, which was conducted across a number of countries including United States, between May 2022 and November 2022. The DSP was an observational study of clinical practice. Treatment practice data were collected by physicians (physician survey) who were asked to provide information for the next 10 patients consulting for migraine. These patients were then invited to fill out a self-completion form (patient survey) providing their own assessment on the disease and treatments.
Interventions
None listed
Sponsors
Pfizer
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who have episodic and/or chronic migraine * Patients age \> 18 * Currently prescribed rimegepant OR triptans for the acute treatment of migraine
Exclusion criteria
* currently prescribed rimegepant for prevention of migraine or for both the acute treatment & prevention of migraine * Rimegepant group: currently prescribed an acute treatment for migraine and other than rimegepant * Triptan Group: currently prescribed an acute treatment for migraine other than triptans
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) | 2 hours post dose (from the data collected retrospectively) | Physicians responded as Yes or No if participants failed to achieve pain freedom within 2 hours post dose. In this outcome measure, number of participants were reported according to physicians' responses. Participant who failed to achieve pain freedom at 2 hours post dose on more than half of the occasion were reported in this outcome measure. |
| Number of Participants Who Reported Migraine Pain Freedom (Success) Within 2 Hours Post Dose (Participants Perspective) | 2 hours post dose (from the data collected retrospectively) | Number of participants who reported migraine pain freedom within 2 hours post dosing in 0 out of every 5 attacks, 1 out of every 5 attacks, 2 out of every 5 attacks, 3 out of every 5 attacks, 4 out of every 5 attacks, or 5 out of every 5 attacks were recorded. Success was defined as responses to '4 out of every 5 attacks' or '5 out of every 5 attacks' combined. In this outcome measure, number of participants with 'success' were reported as per participants' responses. Participant who reported migraine pain freedom (success) at 2 hours post dose on more than half of occasion were reported in this outcome measure. |
| Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Over the last 3 months prior completing the survey | Physicians' satisfaction with current acute treatment for migraine was recorded and classified as extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied and extremely dissatisfied. In this outcome measure number of participants were reported per each category according to physicians' responses. |
| Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Over the last 3 months prior completing the survey | Physicians' reported reasons for lack of satisfaction with current acute treatment. In this outcome measure number of participants were reported per each reason according to physicians' responses. There could be more than 1 reason for lack of satisfaction per participant. |
| Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Over the last 3 months prior completing the survey | Participants' satisfaction with current acute treatment for migraine was recorded and classified as extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied and extremely dissatisfied. In this outcome measure number of participants were reported per each category according to participants' responses. |
| Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | Over the last 3 months prior completing the survey | Participants' reported reasons for lack of satisfaction with current acute treatment. In this outcome measure, number of participants were reported per each reason according to participants' responses. There could be more than 1 reason for lack of satisfaction per participant. |
| Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective) | Over the last 3 months prior completing the survey | Participants responded about their willingness to continue use of acute treatment and responses were classified as definitely yes, probably yes, do not know, probably not, definitely not. Willingness to continue was defined as responses to: 'Definitely yes' or 'Probably yes' combined. Unwillingness to continue was defined as responses to 'Probably not' and 'Definitely not' combined. In this outcome measure number of participants were reported according to participants' responses. |
| Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Over the last 3 months prior completing the survey | mTOQ6 was participants reported questionnaire and participants had to respond on following 6 items: 1) Are you able to quickly return to your normal activities (i.e., work, family, leisure, social activities) after taking your migraine medication?; 2) After taking your migraine medication, are you pain free within 2 hours for most attacks?; 3) Does one dose of your migraine medication usually relieve your headache and keep it away for at least 24 hours?; 4) Is your migraine medication well tolerated?; 5) Are you comfortable enough with your migraine medication to be able to plan your daily activities?; and 6) After taking your migraine medication, do you feel in control of your migraines enough so that you feel there will be no disruption to your daily activities?. Each item had following responses: never, rarely, less than half the time and half the time or more. |
| Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | Over the last 3 months prior completing the survey | In this outcome measure number of participants were classified based on timing/when they took acute treatment as follows: 1) before any sign of a migraine attack, but in anticipation of one starting; 2) at the first sign of a migraine attack (before the pain started); 3) when the pain started; 4) after the pain had started and participant had an idea of pain's severity. |
| Mean of Number of Days Per Month Participants Took Acute Prescription Treatment | Over the last 3 months prior completing the survey | In this outcome measure mean of number of days per month participants took acute prescription treatment were recorded. |
Countries
United States
Participant flow
Recruitment details
Data was extracted from Adelphi Real World (ARW) Migraine VII Disease Specific Programme (DSP) 2022 database. Participants diagnosed with migraine and prescribed rimegepant or triptans as an acute treatment for their migraine in the US, were recruited into the Migraine VII DSP US between May 2022 and November 2022. This retrospective observational study comprised secondary data analysis of DSP data.
Participants by arm
| Arm | Count |
|---|---|
| Rimegepant Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study. | 91 |
| Triptans Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study. | 437 |
| Total | 528 |
Baseline characteristics
| Characteristic | Triptans | Total | Rimegepant |
|---|---|---|---|
| Age, Continuous | 38.98 Years STANDARD_DEVIATION 13.4 | 38.99 Years STANDARD_DEVIATION 13.34 | 39.01 Years STANDARD_DEVIATION 13.11 |
| Race/Ethnicity, Customized African American | 65 Participants | 77 Participants | 12 Participants |
| Race/Ethnicity, Customized Asian (Indian subcontinent) | 8 Participants | 8 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian (other) | 8 Participants | 10 Participants | 2 Participants |
| Race/Ethnicity, Customized Hispanic / Latino / Latina | 38 Participants | 46 Participants | 8 Participants |
| Race/Ethnicity, Customized Middle Eastern | 8 Participants | 10 Participants | 2 Participants |
| Race/Ethnicity, Customized Native American | 1 Participants | 2 Participants | 1 Participants |
| Race/Ethnicity, Customized South-East Asian | 8 Participants | 9 Participants | 1 Participants |
| Race/Ethnicity, Customized White/Caucasian | 304 Participants | 369 Participants | 65 Participants |
| Sex: Female, Male Female | 309 Participants | 375 Participants | 66 Participants |
| Sex: Female, Male Male | 128 Participants | 151 Participants | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Mean of Number of Days Per Month Participants Took Acute Prescription Treatment
In this outcome measure mean of number of days per month participants took acute prescription treatment were recorded.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rimegepant | Mean of Number of Days Per Month Participants Took Acute Prescription Treatment | 3.29 Days per month | Standard Deviation 1.71 |
| Triptans | Mean of Number of Days Per Month Participants Took Acute Prescription Treatment | 4.04 Days per month | Standard Deviation 4.82 |
Primary
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
mTOQ6 was participants reported questionnaire and participants had to respond on following 6 items: 1) Are you able to quickly return to your normal activities (i.e., work, family, leisure, social activities) after taking your migraine medication?; 2) After taking your migraine medication, are you pain free within 2 hours for most attacks?; 3) Does one dose of your migraine medication usually relieve your headache and keep it away for at least 24 hours?; 4) Is your migraine medication well tolerated?; 5) Are you comfortable enough with your migraine medication to be able to plan your daily activities?; and 6) After taking your migraine medication, do you feel in control of your migraines enough so that you feel there will be no disruption to your daily activities?. Each item had following responses: never, rarely, less than half the time and half the time or more.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure and Number Analyzed signifies number of participants evaluable for specified rows.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Less than half the time | 1 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Rarely | 2 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Half the time or more | 26 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Less than half the time | 1 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Rarely | 2 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Half the time or more | 27 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Never | 0 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Never | 0 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Never | 1 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Rarely | 1 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Rarely | 2 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Less than half the time | 2 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Rarely | 1 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Half the time or more | 27 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Never | 0 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Never | 0 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Less than half the time | 1 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Rarely | 1 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Half the time or more | 27 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Less than half the time | 0 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Half the time or more | 27 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Half the time or more | 29 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Less than half the time | 2 Participants |
| Rimegepant | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Never | 0 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Half the time or more | 84 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Rarely | 10 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Less than half the time | 14 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Half the time or more | 83 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Never | 2 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Rarely | 5 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Less than half the time | 17 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 6 | Half the time or more | 82 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Never | 1 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Rarely | 7 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Less than half the time | 14 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 1 | Half the time or more | 86 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Never | 2 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Rarely | 8 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 2 | Less than half the time | 15 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Never | 2 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Rarely | 6 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Less than half the time | 14 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 3 | Half the time or more | 86 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Never | 0 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Rarely | 7 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Less than half the time | 11 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 4 | Half the time or more | 88 Participants |
| Triptans | Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) | Item 5 | Never | 1 Participants |
Primary
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
Participants' reported reasons for lack of satisfaction with current acute treatment. In this outcome measure, number of participants were reported per each reason according to participants' responses. There could be more than 1 reason for lack of satisfaction per participant.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It reduces my migraine pain by less than half | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I am not happy with the way I have to take it | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It does not work as well as it used to | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I find it difficult to know when to take it | 1 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I have too many different acute treatments to take | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It only reduces my migraine pain by half | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I worry about becoming dependent on it | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | The number of side effects I experience | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It costs me too much money | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It does not work quickly enough | 1 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | Other | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | The severity of the side effects I experience | 0 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | Other | 3 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It only reduces my migraine pain by half | 3 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It reduces my migraine pain by less than half | 1 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It does not work quickly enough | 5 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It does not work as well as it used to | 5 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | The number of side effects I experience | 1 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | The severity of the side effects I experience | 1 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I am not happy with the way I have to take it | 2 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I have too many different acute treatments to take | 1 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I worry about becoming dependent on it | 1 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | It costs me too much money | 1 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) | I find it difficult to know when to take it | 3 Participants |
Primary
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Physicians' reported reasons for lack of satisfaction with current acute treatment. In this outcome measure number of participants were reported per each reason according to physicians' responses. There could be more than 1 reason for lack of satisfaction per participant.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Slow onset of action | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Mode of administration | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Number of side effects experienced | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | The number of prescribed acute treatments | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Efficacy diminished over time | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | The treatment is costly for the participant | 2 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Severity of side effects experienced | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Other | 1 Participants |
| Rimegepant | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Lack of efficacy | 3 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Other | 7 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Lack of efficacy | 26 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Slow onset of action | 13 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Efficacy diminished over time | 17 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Number of side effects experienced | 8 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Severity of side effects experienced | 1 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | Mode of administration | 2 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | The number of prescribed acute treatments | 2 Participants |
| Triptans | Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) | The treatment is costly for the participant | 1 Participants |
Primary
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Participants' satisfaction with current acute treatment for migraine was recorded and classified as extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied and extremely dissatisfied. In this outcome measure number of participants were reported per each category according to participants' responses.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Extremely satisfied | 17 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Slightly dissatisfied | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Slightly satisfied | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Dissatisfied | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Satisfied | 11 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Extremely dissatisfied | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Neither satisfied nor dissatisfied | 1 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Extremely dissatisfied | 1 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Extremely satisfied | 23 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Satisfied | 57 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Slightly satisfied | 11 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Neither satisfied nor dissatisfied | 5 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Slightly dissatisfied | 5 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) | Dissatisfied | 1 Participants |
Primary
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Physicians' satisfaction with current acute treatment for migraine was recorded and classified as extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied and extremely dissatisfied. In this outcome measure number of participants were reported per each category according to physicians' responses.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Slightly satisfied | 2 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Slightly dissatisfied | 2 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Satisfied | 31 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Dissatisfied | 1 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Neither satisfied nor dissatisfied | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Extremely dissatisfied | 0 Participants |
| Rimegepant | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Extremely satisfied | 55 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Extremely dissatisfied | 1 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Extremely satisfied | 103 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Satisfied | 276 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Slightly satisfied | 33 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Neither satisfied nor dissatisfied | 12 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Slightly dissatisfied | 10 Participants |
| Triptans | Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) | Dissatisfied | 2 Participants |
Primary
Number of Participants Classified Based on Timing They Took Acute Prescription Treatment
In this outcome measure number of participants were classified based on timing/when they took acute treatment as follows: 1) before any sign of a migraine attack, but in anticipation of one starting; 2) at the first sign of a migraine attack (before the pain started); 3) when the pain started; 4) after the pain had started and participant had an idea of pain's severity.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rimegepant | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | At the first sign of a migraine attack (before the pain started) | 21 Participants |
| Rimegepant | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | After the pain has started and participant had an idea of how severe it was | 1 Participants |
| Rimegepant | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | When the pain started | 4 Participants |
| Rimegepant | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | Before any sign of a migraine attack, but in anticipation of one starting | 3 Participants |
| Triptans | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | When the pain started | 15 Participants |
| Triptans | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | At the first sign of a migraine attack (before the pain started) | 76 Participants |
| Triptans | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | Before any sign of a migraine attack, but in anticipation of one starting | 10 Participants |
| Triptans | Number of Participants Classified Based on Timing They Took Acute Prescription Treatment | After the pain has started and participant had an idea of how severe it was | 3 Participants |
Primary
Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective)
Physicians responded as Yes or No if participants failed to achieve pain freedom within 2 hours post dose. In this outcome measure, number of participants were reported according to physicians' responses. Participant who failed to achieve pain freedom at 2 hours post dose on more than half of the occasion were reported in this outcome measure.
Time frame: 2 hours post dose (from the data collected retrospectively)
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rimegepant | Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) | Yes | 23 Participants |
| Rimegepant | Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) | No | 63 Participants |
| Triptans | Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) | Yes | 167 Participants |
| Triptans | Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) | No | 217 Participants |
Primary
Number of Participants Who Reported Migraine Pain Freedom (Success) Within 2 Hours Post Dose (Participants Perspective)
Number of participants who reported migraine pain freedom within 2 hours post dosing in 0 out of every 5 attacks, 1 out of every 5 attacks, 2 out of every 5 attacks, 3 out of every 5 attacks, 4 out of every 5 attacks, or 5 out of every 5 attacks were recorded. Success was defined as responses to '4 out of every 5 attacks' or '5 out of every 5 attacks' combined. In this outcome measure, number of participants with 'success' were reported as per participants' responses. Participant who reported migraine pain freedom (success) at 2 hours post dose on more than half of occasion were reported in this outcome measure.
Time frame: 2 hours post dose (from the data collected retrospectively)
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Rimegepant | Number of Participants Who Reported Migraine Pain Freedom (Success) Within 2 Hours Post Dose (Participants Perspective) | 22 Participants |
| Triptans | Number of Participants Who Reported Migraine Pain Freedom (Success) Within 2 Hours Post Dose (Participants Perspective) | 67 Participants |
Primary
Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective)
Participants responded about their willingness to continue use of acute treatment and responses were classified as definitely yes, probably yes, do not know, probably not, definitely not. Willingness to continue was defined as responses to: 'Definitely yes' or 'Probably yes' combined. Unwillingness to continue was defined as responses to 'Probably not' and 'Definitely not' combined. In this outcome measure number of participants were reported according to participants' responses.
Time frame: Over the last 3 months prior completing the survey
Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Rimegepant | Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective) | Willing to continue | 28 Participants |
| Rimegepant | Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective) | Unwilling to continue | 1 Participants |
| Triptans | Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective) | Willing to continue | 92 Participants |
| Triptans | Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective) | Unwilling to continue | 2 Participants |